In addition, treatment with the Nlrp3 inflammasome selective inhibitors OLT1177 and Z-WHED-FMK markedly ameliorated DENV- and EIII-induced platelet defects in vitro and in vivo, suggesting that the Nlrp3 inflammasome can be a feasible target for treating dengue-associated thrombocytopenia and platelet defects. This evidence concerns the gene NLRP3 and Thrombocytopenia.